Viewing Study NCT00105209



Ignite Creation Date: 2024-05-05 @ 11:39 AM
Last Modification Date: 2024-10-26 @ 9:11 AM
Study NCT ID: NCT00105209
Status: COMPLETED
Last Update Posted: 2005-06-24
First Post: 2005-03-09

Brief Title: A Study of Aspirin and Clopidogrel in Patients With Idiopathic Pulmonary Arterial Hypertension
Sponsor: Kawut Steven MD
Organization: Kawut Steven MD

Study Overview

Official Title: A Double-Blind Placebo-Controlled Three Treatment Cross-Over Study of Aspirin and Clopidogrel in Patients With Idiopathic Pulmonary Arterial Hypertension
Status: COMPLETED
Status Verified Date: 2005-03
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: Rationale Idiopathic pulmonary arterial hypertension IPAH is characterized by in situ thrombosis and increased thromboxane A2 Tx-M synthesis While both may be attributable to abnormal platelet function there are no studies of anti-platelet therapy in IPAH

Objectives The purpose of this study is to assess the effects of aspirin ASA and clopidogrel on platelet function and eicosanoid metabolism in patients with IPAH
Detailed Description: This is a randomized double-blind placebo-controlled crossover study of aspirin 81 mg once daily and clopidogrel 75 mg once daily Platelet function is assessed with plasma P-selectin levels and aggregometry after exposure to adenosine diphosphate arachidonic acid and collagen We will assess serum levels of thromboxane B2 and urinary metabolites of thromboxane A2 and prostaglandin I2 Tx-M and PGI-M respectively

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None
Secondary IDs
Secondary ID Type Domain Link
RR00095 None None None
RR00645 None None None
RR15534 None None None